ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

• Clara I. Aceves-Luquero,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Anupriya Agarwal,

  Affiliation Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon, United States of America

  ⨯
• Juan L. Callejas-Valera,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Laura Arias-González,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Azucena Esparís-Ogando,

  Affiliation Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain

  ⨯
• Luis del Peso Ovalle,

  Affiliation Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

  ⨯
• Itxaso Bellón-Echeverria,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Miguel A. de la Cruz-Morcillo,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Eva M. Galán Moya,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Inmaculada Moreno Gimeno,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Juan C. Gómez,

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯
• Michael W. Deininger,

  Affiliation Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon, United States of America

  ⨯
• Atanasio Pandiella,

  Affiliation Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain

  ⨯
• Ricardo Sánchez Prieto

  * E-mail: ricardo.sanchez@uclm.es

  Affiliation CRIB/Facultad de Medicina, UCLM, Albacete, Spain

  ⨯